A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia

Fadlyana, Eddy; Rusmil, Kusnandi; Tarigan, Rodman; Reza Rahmadi, Andri; Prodjosoewojo, Susantina; Sofiatin, Yulia; Vravita Khrisna, Citra; Mulia Sari, Rini; Setyaningsih, Lilis; Surachman, Fikrianti; Sjafri Bachtiar, Novilia; Sukandar, Hadyana; Megantara, Imam; Murad, Chrysanti; Nur Andriana Pangesti, Krisna; Setiawaty, Vivi; Sudigdoadi, Sunarjati; Hu, Yaling; Gao, Qiang; B. Kartasasmita, Cissy

doi:10.1016/j.vaccine.2021.09.052

Public

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia

Published in Vaccine • Sep 24, 2021

Authors:

Eddy Fadlyana

Kusnandi Rusmil

Rodman Tarigan

Abstract

BACKGROUND: The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID...

Subject

Medicine

Immunogenicity

Seroconversion

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!